Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Date:6/8/2008

tion of SB-509 in diabetics with moderate to severe diabetic peripheral sensory motor neuropathy in the legs. The trial is being conducted at multiple sites, accrual has been completed and plans recently announced to expand the study and enroll additional subjects.

In the initial trial, 45 subjects have completed enrollment. Subjects were randomized to one of two groups in a 2:1 ratio. The larger group (approximately 30 subjects) was treated by intramuscular injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into the lower limb and will be treated every 3 months. The remaining group (approximately 15 subjects) received an equal volume of placebo on the same schedule. Each subject will receive a total of two treatments (Day 0 and 90). Subjects receive injections in a distribution pattern that targets the major peripheral nerves in the legs and feet.

As announced on June 6, 2008, Sangamo will expand the Phase 2 study by enrolling approximately 45 additional subjects in the trial. Subjects will again be randomized to one of two groups in a 2:1 ratio. The larger group (approximately 30 subjects) will be treated by intramuscular injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into the lower limb every 2 months. The remaining group (approximately 15 subjects) will receive an equal volume of placebo on the same schedule. Each subject will receive a total of three treatments (Day 0, 60 and 120). Subjects will receive injections in the same pattern used in the initial part of the trial.

The symptoms of diabetic peripheral neuropathy and any changes that occur during the trial will be evaluated based on neurological examination data, electrophysiological testing data, subject neurological questionnaire, and subject pain assessment. Specifically, investigators will assess pain using VASPI, and use scoring systems such as a modified NIS-LL and TNS to quantify neurologic exam and assess signs and symptoms of the condition.

For each subject
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
6. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3, 2015  The findings of ... raising disturbing questions about the company,s handling of its ... reports.  On September 2 nd , part one ... adverse events, including at least 27 fatalities, have been ... a confidential study commissioned by C.R. Bard in 2004 ...
(Date:9/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/4q3mv2/investigation ) ... on China Olmesartan Market, 2010-2019" report to their ... successfully developed by Sankyo Pharmaceuticals Co., Ltd and was ... was approved by FDA to enter the American market ... drug in the world after it succeeded in the ...
(Date:9/3/2015)... Sept. 3, 2015 Research and Markets ... the "Investigation Report on China Tamsulosin Market, ... Compared with other a1- adrenergic receptor blockers, ... and lower risk of urinary tract infections and ... its debut in 1993 in Japan ...
Breaking Medicine Technology:IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 2IVC Filter Lawsuit News: NBC News Investigation into C.R. Bard Recovery Filters Raises Disturbing Questions, Bernstein Liebhard LLP Reports 3China Olmesartan Investigation Market Report 2010-2019 2China Tamsulosin Market Investigation Report 2015 2
... 2010 ViroPharma Incorporated (Nasdaq: VPHM ) ... Cinryze ® (C1 esterase inhibitor [human]) at the ... (WAO), December 5 through 8 in Dubai, UAE.   ... these data, which were first presented at the November ...
... Healthcare, a world-leading developer, manufacturer and marketer of innovative ... that in connection with a refinancing of its debt ... in combination with new senior secured credit facilities, it ... Senior Notes. The offering of the new notes will ...
Cached Medicine Technology:Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 2Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 3Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 4Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 5Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 6Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 7Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 8Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO) 9ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 2ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 3
(Date:9/3/2015)... ... 03, 2015 , ... Girl’s Night Out to benefit Core Compassion Project will ... Kate Road in Monroe, North Carolina. The event food will be provided ... Kate Clyde’s offers off-premise catering and event services from casual to elegant. They are ...
(Date:9/3/2015)... ... September 03, 2015 , ... For the second ... Annual Inc. 5000 list of fastest-growing private companies in America. President and ... the nation's companies have demonstrated such remarkably consistent high growth, particularly in the ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... providers, has been retained to lead a national chief executive officer ... search firms in the healthcare industry, B. E. Smith has recently placed more ...
(Date:9/3/2015)... ... 03, 2015 , ... According to an Oncology Nurse Advisor article ... patients with oropharyngeal cancer (oral cancer) to be successfully diagnosed and treated for relapses ... HPV infections, which have a high rate of success in treatment and elimination of ...
(Date:9/3/2015)... ... 03, 2015 , ... As a result of the Patient ... health insurance plans, more employers are moving to a self-funded model for pharmacy ... 2014 United Benefit Advisors (UBA) Health Plan Survey. , UBA’s survey, the nation’s ...
Breaking Medicine News(10 mins):Health News:Girl’s Night Out, with Food From Kate Clyde's Catered Creations, to Benefit Core Compassion Project 2Health News:Inc. 5000 Includes Intellicure, Inc., Two Years in a Row 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 3Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4
... N.J., March 27 Zydus Pharmaceuticals announced today that ... and Drug Administration (FDA) for its Abbreviated New Drug ... and 200mg. This product is available for immediate ... patients 10 years old or older with partial onset ...
... Michigan, there are not enough jobs in manufacturing and ... to overshadow supply is health care, particularly physicians.The health ... difficulty of becoming a doctor have led to a ... projected to get worse, according to the Michigan State ...
... Stats show safety programs need to be extended to others ... (HealthDay News) -- Only one-third of people killed in fatal ... report shows. , The other two-thirds of victims are passengers, ... to the AAA Foundation for Traffic Safety. , "For every ...
... Women,s Voices for the Health Care We NeedNEW YORK, March ... debate the merits and costs of health reform, women around ... our families. For many women and our families, health reform ... York City will speak out publicly about the problems they ...
... of a program established in Uganda last year, the ... (HVO) have again partnered to launch a new hematology ... Empresa De Seguros De Salud (EsSalud). The goal of ... clinicians, laboratory technicians, technologists, and students. This training will ...
... unlocks the virus from latent state , , FRIDAY, March 27 ... in the ongoing quest for a treatment, and possibly a ... as VP16 is apparently responsible for pushing herpes out of ... , Experts estimate that 70 percent to 90 percent of ...
Cached Medicine News:Health News:As Physician Shortage Looms, Recognize Your Doctor On March 30, National Doctors' Day 2Health News:Most Fatalities in Teen Crashes Are Not the Drivers 2Health News:Women's Speak-Out for Action on Health Care Reform 2Health News:ASH and HVO Partner to Launch Hematology Program in Peru 2Health News:ASH and HVO Partner to Launch Hematology Program in Peru 3Health News:Treatment Target for Herpes Pinpointed 2
Inquire...
Inquire...
A professionally designed instrument for obtaining accurate measurements of the corneal curvature. The convenient configuration also facilitates measuring contact lens curvatures....
... best 32-bit software package (IMAGEnet 2000) with ... bring you a fast reliable solution to ... advantage of the Compaq EN Series small ... technology and a formidable grouping of other ...
Medicine Products: